MCID: INT017
MIFTS: 49

Intestinal Schistosomiasis

Categories: Blood diseases, Gastrointestinal diseases, Infectious diseases

Aliases & Classifications for Intestinal Schistosomiasis

MalaCards integrated aliases for Intestinal Schistosomiasis:

Name: Intestinal Schistosomiasis 12 15 72
Schistosomiasis Japonica 12 44 17 72
Schistosomiasis Mansoni 44 17 72
Katayama Fever 12 72
Schistosoma Mansoni Infectious Disease 12
Schistosoma Japonicum Infection 12
Schistosomiasis 72

Classifications:



External Ids:

Disease Ontology 12 DOID:0050597
ICD9CM 35 120.1 120.2
ICD10 33 B65.1 B65.2
UMLS 72 C0036323 C0036329 C0036330 more

Summaries for Intestinal Schistosomiasis

Disease Ontology : 12 A schistosomiasis that involves parasitic infection of the intestine caused by Schistosoma mansoni, Schistosoma intercalatum or Schistosomiasis japonicum. The symptoms include fever, cough, abdominal pain, diarrhea, hepatosplenomegaly, colonic polyposis with bloody diarrhea and eosinophilia.

MalaCards based summary : Intestinal Schistosomiasis, also known as schistosomiasis japonica, is related to schistosomiasis and cytokine deficiency. An important gene associated with Intestinal Schistosomiasis is IL13 (Interleukin 13), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PAK Pathway. The drugs Lumefantrine and Artemether have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and colon, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 75 Schistosoma mansoni is a water-borne parasite of humans, and belongs to the group of blood flukes... more...

Related Diseases for Intestinal Schistosomiasis

Diseases related to Intestinal Schistosomiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 277)
# Related Disease Score Top Affiliating Genes
1 schistosomiasis 31.4 STAT6 IL5 IL4 IL13 ARG1
2 cytokine deficiency 31.3 IL5 IL13
3 paragonimiasis 31.0 IL5 IL13
4 leishmaniasis 30.8 IL5 IL4 IL13
5 ascaris lumbricoides infection 30.7 IL5 IL13
6 trichinosis 30.6 IL5 IL4
7 strongyloidiasis 30.5 IL5 IL13
8 cercarial dermatitis 30.5 SNAI1 IL5
9 allergic hypersensitivity disease 30.5 IL5 IL4 IL13
10 tetanus 30.3 IL5 IL4 IL13
11 hypereosinophilic syndrome 30.3 IL5 IL4 IL13
12 proteasome-associated autoinflammatory syndrome 1 30.3 IL5 IL4 IL13
13 inflammatory bowel disease 30.3 STAT6 IL4 IL13
14 allergic asthma 29.9 STAT6 IL5 IL4 IL13
15 urinary schistosomiasis 29.8 STAT6 IL5 IL4 IL13
16 parasitic helminthiasis infectious disease 29.0 SRCIN1 SNAI1 IL5 IL4 IL13 CHRM2
17 schistosoma mansoni infection, susceptibility/ 11.4
18 angioimmunoblastic lymphadenopathy with dysproteinemia 10.6 IL5 IL13
19 respiratory syncytial virus infectious disease 10.6 IL5 IL13
20 esophagitis, eosinophilic, 1 10.5 IL5 IL13
21 hepatocellular carcinoma 10.5
22 cough variant asthma 10.5 IL5 IL4
23 egg allergy 10.5 IL5 IL4
24 intestinal volvulus 10.5 SRCIN1 IL5
25 scleritis 10.5 IL5 IL4
26 atopic keratoconjunctivitis 10.5 IL5 IL4
27 sulfamethoxazole allergy 10.5 IL5 IL4
28 radiculopathy 10.5 IL5 IL13
29 intrinsic asthma 10.5 IL5 IL4
30 salmonellosis 10.4
31 gaucher disease, type ii 10.4 IL5 IL4
32 non-suppurative otitis media 10.4 IL5 IL4
33 pollen allergy 10.4 IL5 IL13
34 kimura disease 10.4 IL5 IL4
35 viral hepatitis 10.4
36 toxic oil syndrome 10.4 IL5 IL4
37 folliculitis 10.4 IL5 IL4
38 mycoplasma pneumoniae pneumonia 10.4 IL4 IL13
39 anterior scleritis 10.4 SRCIN1 IL5
40 night blindness, congenital stationary, type 1a 10.3 IL5 IL13
41 autoimmune disease 10.3
42 liver cirrhosis 10.3
43 chagas disease 10.3
44 intestinal disease 10.3
45 milk allergy 10.3 IL5 IL4
46 allergic bronchopulmonary aspergillosis 10.3 IL5 IL4
47 nickel allergic contact dermatitis 10.3 IL5 IL4 IL13
48 dermatitis 10.3 IL5 IL4 IL13
49 inflammatory bowel disease 4 10.3 IL5 IL4 IL13
50 angiostrongyliasis 10.3 IL5 IL4 IL13

Graphical network of the top 20 diseases related to Intestinal Schistosomiasis:



Diseases related to Intestinal Schistosomiasis

Symptoms & Phenotypes for Intestinal Schistosomiasis

MGI Mouse Phenotypes related to Intestinal Schistosomiasis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.02 ARG1 CD4 IL13 IL4 IL5 PRDX2
2 homeostasis/metabolism MP:0005376 10.02 ARG1 CD4 CHRM2 IL13 IL4 IL5
3 growth/size/body region MP:0005378 10.01 CD4 CHRM2 IL13 IL4 IL5 SNAI1
4 immune system MP:0005387 9.86 ARG1 CD4 IL13 IL4 IL5 PRDX2
5 integument MP:0010771 9.63 CD4 CHRM2 IL13 IL4 STAT6 THBS2
6 nervous system MP:0003631 9.56 ARG1 CD4 CHRM2 IL13 IL4 SNAI1
7 respiratory system MP:0005388 9.1 CHRM2 IL13 IL4 IL5 STAT6 THBS2

Drugs & Therapeutics for Intestinal Schistosomiasis

Drugs for Intestinal Schistosomiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lumefantrine Approved Phase 4 82186-77-4 6437380
2
Artemether Approved Phase 4 71963-77-4 68911 119380
3 Artemether, Lumefantrine Drug Combination Phase 4
4
Myrrh Approved Phase 3 9000-45-7
5
Albendazole Approved, Vet_approved Phase 3 54965-21-8 2082
6
Sulfadoxine Approved, Investigational Phase 3 2447-57-6 17134
7
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
8
leucovorin Approved Phase 3 58-05-9 143 6006
9
Triclabendazole Approved, Investigational Phase 3 68786-66-3
10
Zinc sulfate Approved, Investigational Phase 2, Phase 3 7733-02-0
11
Zinc Approved, Investigational Phase 2, Phase 3 7440-66-6 32051
12
Amodiaquine Approved, Investigational Phase 3 86-42-0 2165
13
Tranexamic Acid Approved Phase 3 1197-18-8 5526
14
Mefloquine Approved, Investigational Phase 3 53230-10-7 4046
15
Artesunate Approved, Investigational Phase 3 88495-63-0 5464098 6917864
16
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
17
Dihydroartemisinin Experimental, Investigational Phase 3 71939-50-9 6918483
18
Piperaquine Experimental, Investigational Phase 3 4085-31-8 5079497
19 Iron Supplement Phase 3
20 Hematinics Phase 3
21 Ferric Compounds Phase 3
22 Tubulin Modulators Phase 3
23 Antimitotic Agents Phase 3
24 Micronutrients Phase 2, Phase 3
25 Trace Elements Phase 2, Phase 3
26 Fanasil, pyrimethamine drug combination Phase 3
27 Folic Acid Antagonists Phase 3
28 Renal Agents Phase 3
29 Sulfalene Phase 3
30 Vitamin B9 Phase 3
31 Vitamin B Complex Phase 3
32 Folate Phase 3
33 Anti-Infective Agents, Urinary Phase 3
34 Nutrients Phase 2, Phase 3
35 Dermatologic Agents Phase 2, Phase 3
36 Astringents Phase 2, Phase 3
37 Artemisinins Phase 3
38 Artemisinine Phase 3
39 Hemostatics Phase 3
40 Coagulants Phase 3
41 Antifibrinolytic Agents Phase 3
42 Antiprotozoal Agents Phase 3
43 Antimalarials Phase 3
44 Antiviral Agents Phase 3
45
Aluminum hydroxide Approved, Investigational Phase 1, Phase 2 21645-51-2
46
Sodium citrate Approved, Investigational Phase 1, Phase 2 68-04-2
47
Indian frankincense Approved, Experimental, Investigational Phase 1, Phase 2
48
Citric acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 77-92-9 311
49
Calcium Approved, Nutraceutical Phase 1, Phase 2 7440-70-2 271
50
Imidazole Experimental, Investigational Phase 1, Phase 2 288-32-4 795

Interventional clinical trials:

(show top 50) (show all 84)
# Name Status NCT ID Phase Drugs
1 The Impact of Intermittent Preventive Malaria Treatment With Artemisinin Combination Therapy (ACT) on Hemoglobin, Malaria, Schistosomiasis, and School Attention Among Primary Schoolchildren in the Kassena-Nankana Districts, Ghana Unknown status NCT01459146 Phase 4 Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel
2 Effect of Schistosomiasis Mansoni and Its Treatment on HIV Susceptibility and Female Genital Immunology Completed NCT02878564 Phase 4 Praziquantel
3 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Highly Endemic Areas of Northeastern Brazil Completed NCT00403611 Phase 4 Praziquantel 60 mg/kg;Praziquantel 40 mg/kg
4 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study Withdrawn NCT02734186 Phase 4 Praziquantel
5 Efficacy of Chinese-made Versus WHO-PQ Praziquantel for Treatment of Schistosoma Haematobium in Zanzibar: a Randomized Controlled Trial Unknown status NCT03133832 Phase 3 Companion Tablet
6 Intravenous Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania Unknown status NCT02541708 Phase 3 Ferric carboxymaltose;Ferrous sulfate + folic acid
7 Safety and Efficacy of Mirazid for Schistosomiasis Treatment as Compared to Praziquantel: An Open-label Randomized Non-placebo-Controlled Study Completed NCT01529710 Phase 3 Myrrh
8 Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST): An Open Label, Randomized Controlled Trial of Single vs. Multiple Treatments of Praziquantel in Intestinal African Schistosomiasis in Côte d'Ivoire Completed NCT02868385 Phase 3 4x Praziquantel;1x Praziquantel
9 Schistosoma Haematobium Infections Among Schoolchildren in Central Sudan One Year After Treatment With Praziquantel Completed NCT01558336 Phase 3 praziquantel
10 Efficacy and Safety Evaluation of the Therapeutic Vaccine Candidate Sh28GST in Association With Praziquantel (PZQ) for Prevention of Clinical and Parasitological Recurrences of S. Haematobium Infection in Children Completed NCT00870649 Phase 3
11 Open-label, Randomized Clinical Trial in Kenya to Determine the Effectiveness of Artesunate + Sulfamethoxypyrazine/Pyrimethamine Vs. Praziquantel in the Treatment of S. Mansoni in Children Completed NCT01054651 Phase 3 Artesunate+Sulfamethoxypyrazine/pyrimethamine;Praziquantel
12 Efficacy and Safety of Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine Regimens Delivered Through Intermittent Preventive Treatment in Schoolchildren of Democratic Republic of Congo: A Randomised Control Trial Completed NCT01722539 Phase 3 Sulfadoxine-pyrimethamine;Piperaquine;Albendazole;Praziquantel
13 A Randomized, Double Blind, Controlled Study to Determine the Efficacy of Zinc Supplementation on Diarrhea Incidence in an Adult Population in Western Kenya. Completed NCT01166815 Phase 2, Phase 3
14 Prospective, Observational Study to Assess the Performance of CAA Measurement as a Diagnostic Tool for the Detection of Schistosoma Haematobium Infections in Pregnant Women and Their Newborn and Child in Lambaréné, Gabon Recruiting NCT03779347 Phase 3 Praziquantel
15 Effectiveness and Safety of Intermittent Preventive Treatment for Malaria Using Either Dihydroartemisinin-piperaquine or Artesunate-amodiaquine in Reducing Malaria Related Morbidities and Improving Cognitive Ability in School-aged Children in Tanzania: A Controlled Randomised Trial Recruiting NCT03640403 Phase 3 Dihydroartemisinin-piperaquine;Artesunate-amodiaquine
16 Tranexamic Acid for the Treatment of Gastrointestinal Haemorrhage: an International Randomised, Double Blind Placebo Controlled Trial Recruiting NCT01658124 Phase 3 Tranexamic Acid;Placebo
17 An Open Label, Phase III Efficacy and Safety Study of L Praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children 3 Months to 6 Years of Age, Including a 2:1 Randomized, Controlled Cohort of Schistosoma Mansoni Infected Children 4 to 6 Years of Age Treated With L PZQ ODT or Commercial PZQ (Biltricide®) Not yet recruiting NCT03845140 Phase 3 L-PZQ ODT;Biltricide®;L-PZQ ODT
18 A Proof-of-concept Trial to Evaluate Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children Not yet recruiting NCT03893097 Phase 3 Praziquantel;Artesunate + Mefloquine
19 Safety and Efficacy of a Novel Candidate Peptide Vaccine Against HCV Infection in Healthy Volunteers and in Treated (Non-responders/ Responders) Chronic HCV Patients. Clinical Trials Phases I and II Unknown status NCT01718834 Phase 1, Phase 2
20 Intestinal Schistosomiasis in Children Aged 1-5 Years,Morbidity Assessment and the Effect of Praziquantel on Morbidity; Along Lake Victoria Shorelines. Completed NCT01901484 Phase 2 Praziquantel
21 Activity of Mefloquine Against Urinary Schistosomiasis Completed NCT01132248 Phase 2 Mefloquine;S/P
22 Open-label, Dose-finding, 2-parts, Efficacy Phase II Study With Three Formulations (Racemate Raziquantel Commercial Oral Tablets, New Oral Disintegrating Tablets of Racemate Praziquantel and L-praziquantel) in Schistosomiasis (S. Mansoni) Infected Children Aged 2-6 Years (Part 1), Followed by an Assessment of Efficacy and Safety With the Selected Formulation and Dosage in S. Mansoni Infected Infants Aged 3-24 Months (Part 2) Completed NCT02806232 Phase 2 Biltricide (racemate praziquantel) oral tablets;Racemate Praziquantel ODT;Levo Praziquantel ODT
23 S. Japonicum and Pregnancy Outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT) Completed NCT00486863 Phase 2 Praziquantel
24 Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 in Combination With the Adjuvant Glucopyranosyl Lipid A (GLA-SE) in Adults Living in Endemic Regions for S. Mansoni and S. Haematobium in Senegal. A Comparative, Randomized, Open-label Trial Completed NCT03041766 Phase 2 GLA-SE solution
25 Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 Against Schistosomiasis in Senegalese School Children Healthy or Infected With S. Mansoni and/or S. Haematobium. A Comparative, Randomized, Controlled, Open-label Trial Active, not recruiting NCT03799510 Phase 2 GLA-SE solution
26 Phase II PK/PD Driven Dose Finding Trial of Praziquantel in Children Under Four Not yet recruiting NCT03640377 Phase 2 Praziquantel
27 A Phase I/II Trial of the Safety, Immunogenicity, and Efficacy of the Sm-TSP-2/Alhydrogel® Schistosomiasis Vaccine in Healthy Exposed Ugandan Adults Not yet recruiting NCT03910972 Phase 1, Phase 2
28 Treatment of Renal Stones With Frankincense (Boswellic Acid): A Clinical Randomized Trial Not yet recruiting NCT03924596 Phase 1, Phase 2 AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid);Potassium Sodium Hydrogen Citrate
29 A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Completed NCT02337855 Phase 1
30 Phase 1 Study Evaluating Safety and Immunological Criteria of Efficacy of the Recombinant Vaccine Candidate Bilhvax Against Schistosomiasis Completed NCT01512277 Phase 1
31 Praziquantel Pharmacokinetics in Pregnancy and During Lactation Completed NCT01288872 Phase 1 Praziquantel
32 Phase 1 Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Completed NCT01154049 Phase 1
33 Group A Streptococcal Human Challenge Study: Building a Pharyngitis Model to Accelerate Vaccine Development Recruiting NCT03361163 Phase 1
34 A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Active, not recruiting NCT03110757 Phase 1
35 Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Among School Children in Jinja District, Uganda: a Stratified Cluster Randomized Controlled Trial Unknown status NCT01869465
36 Epidemiology of Human Immunodeficiency Virus (HIV-1) and Schistosoma Mansoni Co-infections and Its Impact on Anthelminthic Treatment Outcome Among HIV-1 Infected Individuals in Fishing Communities in Mwanza Region, Northwestern Tanzania. Unknown status NCT01541631 Praziquantel and Albendazole;Praziquantel and Albendazole;Praziquantel and Albendazole
37 Study on the Role of Antioxidant Micronutrients on the Reversal of Schistosomal Peri-portal Fibrosis of the Liver. Unknown status NCT01260012
38 Association of Schistosomiasis Seropositivity With Adverse Birth Events in Migrants From Bilharzia-endemic Areas Unknown status NCT03158298
39 The Evaluation of Glycyrrhizic Acid's Pesticide Effect in Treating Liver Damage (Retrospective Study) Unknown status NCT02329314
40 ANRS 12320 IMMHoTHep : Investigative Mathematical Modeling of Hospital Transmission of Hepatitis C Unknown status NCT02826447
41 Effects of Arachidonic Acid Supplementation on Schistosomiasis Mansoni Infection in Egyptian School Children Completed NCT02144389 Praziquantel (PZQ)
42 Evaluation of Applicability of Urine Based Schistosomiasis Test Strip in the Epidemiologic Mapping and Sampling of Schistosoma Mansoni Infection in Low Endemic Areas of Kenya Completed NCT00463307
43 Treatment of Schistosomal Portal Hypertension: Assessment of Efficacy of Endoscopic Therapy Alone or in the Combined With Surgical Procedure Completed NCT01931826
44 Parasitologic Impact of Different Mass Drug Administration Strategies Against Schistosoma Mansoni in Endemic Areas of Mwanza Region, Tanzania, Where Prevalence is 25% or Above Completed NCT02162875 Praziquantel
45 Establishing a Single-sex Controlled Human Schistosomiasis Infection Model: Safety and Dose Finding Completed NCT02755324
46 Comparison of Schistosomiasis Diagnostic Techniques and Study of Schistosoma Infection on Children's Immune Response to Childhood Vaccines, on Anaemia and on Nutritional Status Completed NCT01553552
47 Assessment of Anaemia Attributable to Schistosomiasis in School Children in Kenya: Mechanisms and Effect of Treatment Completed NCT00414479 praziquantl, iron, ACT
48 Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia Completed NCT00276224 ferrous sulphate (drug)
49 Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control Completed NCT00463632
50 Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Completed NCT00463593

Search NIH Clinical Center for Intestinal Schistosomiasis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Oxamniquine
Praziquantel

Cochrane evidence based reviews: schistosomiasis japonica

Genetic Tests for Intestinal Schistosomiasis

Anatomical Context for Intestinal Schistosomiasis

MalaCards organs/tissues related to Intestinal Schistosomiasis:

41
Liver, Testes, Colon, T Cells, Spleen, Bone, Lung

Publications for Intestinal Schistosomiasis

Articles related to Intestinal Schistosomiasis:

(show top 50) (show all 1524)
# Title Authors PMID Year
1
INF-gamma, IL-5 and IgE profiles in chronic schistosomiasis mansoni Egyptian patients with or without hepatitis C infection. 9 38
16605110 2006
2
The prevalence of schistosomiasis in Uganda: A nationally representative population estimate to inform control programs and water and sanitation interventions. 38
31412023 2019
3
An innovative and user-friendly scoring system for standardised quantitative interpretation of the urine-based point-of-care strip test (POC-CCA) for the diagnosis of intestinal schistosomiasis- a proof-of-concept study. 38
31425672 2019
4
Prevalence and Risk Factors for Schistosomiasis among Schoolchildren in two Settings of Côte d'Ivoire. 38
31340504 2019
5
Prevalence and intensity of Schistosoma mansoni infection in pediatric populations on antiretroviral therapy in north-western Tanzania: a cross-sectional study. 38
31345980 2019
6
Concurrent Schistosoma mansoni and Schistosoma haematobium infections in a peri-urban community along the Weija dam in Ghana: A wake up call for effective National Control Programme. 38
31356786 2019
7
Intestinal schistosomiasis: a very long-lived tropical parasite. 38
30797063 2019
8
A meta-analysis of infection rates of Schistosoma japonicum in sentinel mice associated with infectious waters in mainland China over last 40 years. 38
31173590 2019
9
Multiple Praziquantel Treatments of Schistosoma mansoni Egg-Negative, CCA-Positive Schoolchildren in a Very Low Endemic Setting in Egypt Do Not Consistently Alter CCA Results. 38
31017083 2019
10
Supplementation with micronutrients and schistosomiasis: systematic review and meta-analysis. 38
30983544 2019
11
Concordance of the point-of-care circulating cathodic antigen test for the diagnosis of intestinal schistosomiasis in a low endemicity area. 38
31142379 2019
12
Toxicity of a molluscicide candidate PPU07 against Oncomelania hupensis (Gredler, 1881) and local fish in field evaluation. 38
30690401 2019
13
Reversal of liver fibrosis after splenectomy in a patient with advanced schistosomiasis japonica: A case report with 4-year follow-up. 38
30973870 2019
14
Non-invasive surveillance of Plasmodium infection by real-time PCR analysis of ethanol preserved faeces from Ugandan school children with intestinal schistosomiasis. 38
30935388 2019
15
Qualitative and quantitative proteomic analyses of Schistosoma japonicum eggs and egg-derived secretory-excretory proteins. 38
30992086 2019
16
Comparison of Kato Katz, antibody-based ELISA and droplet digital PCR diagnosis of schistosomiasis japonica: Lessons learnt from a setting of low infection intensity. 38
30830925 2019
17
Distribution pattern of the snail intermediate host of schistosomiasis japonica in the Poyang Lake region of China. 38
30922403 2019
18
Urinary circulating DNA and circulating antigen for diagnosis of schistosomiasis mansoni: a field study. 38
30549391 2019
19
Biomphalaria pfeifferi Snails and Intestinal Schistosomiasis, Lake Malawi, Africa, 2017-2018. 38
30602122 2019
20
Interaction and involvement of cellular adhesion molecules in the pathogenesis of Schistosomiasis mansoni. 38
30503821 2019
21
A case of acute appendicitis due to intestinal schistosomiasis. 38
30555690 2019
22
Transmission of Schistosoma mansoni in Yachi areas, southwestern Ethiopia: new foci. 38
30626428 2019
23
Prevalence and Reinfection Rates of Schistosoma mansoni and Praziquantel Efficacy against the Parasite among Primary School Children in Sanja Town, Northwest Ethiopia. 38
31179124 2019
24
Jejunal Ulcer Caused by Schistosoma japonicum. 38
31049231 2019
25
Detection of Schistosoma mansoni-derived DNA in human urine samples by loop-mediated isothermal amplification (LAMP). 38
30913249 2019
26
β-Actin: Not a Suitable Internal Control of Hepatic Fibrosis Caused by Schistosoma japonicum. 38
30766520 2019
27
Analysis of risk factors and changing trends the infection rate of intestinal schistosomiasis caused by S. japonicum from 2005 to 2014 in Lushan city. 38
30055333 2018
28
Co-parasitism of intestinal protozoa and Schistosoma japonicum in a rural community in the Philippines. 38
30526666 2018
29
Surveillance of intestinal schistosomiasis during control: a comparison of four diagnostic tests across five Ugandan primary schools in the Lake Albert region. 38
29560841 2018
30
Circulating miRNAs as footprints for liver fibrosis grading in schistosomiasis. 38
30482723 2018
31
Schistosoma mansoni infection and socio-behavioural predictors of HIV risk: a cross-sectional study in women from Uganda. 38
30453907 2018
32
Antinuclear antibodies and interleukin responses in patients with Schistosoma japonicum infection. 38
30074250 2018
33
[Endemic status of schistosomiasis in People's Republic of China in 2017]. 38
30567015 2018
34
Effect of miR-182 on hepatic fibrosis induced by Schistosomiasis japonica by targeting FOXO1 through PI3K/AKT signaling pathway. 38
29323718 2018
35
Data on the pre-MDA and post MDA interventions for Schistosoma mansoni and Schistosoma haematobium in a co-endemic focus in Uganda: 1951-2011. 38
30225313 2018
36
The epidemiology of schistosomiasis in Lango region Uganda 60 years after Schwetz 1951: Can schistosomiasis be eliminated through mass drug administration without other supportive control measures? 38
29935144 2018
37
A Spatiotemporal Analysis of Schistosomiasis in Hunan Province, China. 38
30324822 2018
38
New Approach for Controlling Snail Host of Schistosoma mansoni, Biomphalaria alexandrina with Cyanobacterial Strains-Derived C-Phycocyanin. 38
29920163 2018
39
Sm-p80-based schistosomiasis vaccine: double-blind preclinical trial in baboons demonstrates comprehensive prophylactic and parasite transmission-blocking efficacy. 38
30133707 2018
40
Schistosomiasis and hydration status: Schistosoma haematobium, but not Schistosoma mansoni increases urine specific gravity among rural Tanzanian women. 38
29664990 2018
41
Schistosoma mansoni infection is associated with quantitative and qualitative modifications of the mammalian intestinal microbiota. 38
30104612 2018
42
Suppression of Schistosoma japonicum Acetylcholinesterase Affects Parasite Growth and Development. 38
30115897 2018
43
GABA-like immunoreactivity in Biomphalaria: Colocalization with tyrosine hydroxylase-like immunoreactivity in the feeding motor systems of panpulmonate snails. 38
29633264 2018
44
Capacity gaps in health facilities for case management of intestinal schistosomiasis and soil-transmitted helminthiasis in Burundi. 38
29970181 2018
45
A perspective for improving the sensitivity of detection: The application of multi-epitope recombinant antigen in serological analysis of buffalo schistosomiasis. 38
29605156 2018
46
Efficacy of praziquantel treatment regimens in pre-school and school aged children infected with schistosomiasis in sub-Saharan Africa: a systematic review. 38
29986763 2018
47
Estimating the prevalence of schistosomiasis japonica in China: a serological approach. 38
29961423 2018
48
Integrating use of point-of-care circulating cathodic antigen rapid diagnostic tests by community health workers during mass drug administration campaigns to improve uptake of praziquantel treatment among the adult population at Kome Island, North-Western Tanzania: a cluster randomized community trial. 38
29976173 2018
49
IL-7 suppresses macrophage autophagy and promotes liver pathology in Schistosoma japonicum-infected mice. 38
29566311 2018
50
Evaluation of transient elastography in assessing liver fibrosis in patients with advanced schistosomiasis japonica. 38
29355611 2018

Variations for Intestinal Schistosomiasis

Expression for Intestinal Schistosomiasis

Search GEO for disease gene expression data for Intestinal Schistosomiasis.

Pathways for Intestinal Schistosomiasis

Pathways related to Intestinal Schistosomiasis according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.12 STAT6 IL5 IL4 IL13 CD4
2
Show member pathways
13.06 SNAI1 IL5 IL4 IL13 CD4
3
Show member pathways
12.65 IL5 IL4 IL13 CD4
4 12.59 STAT6 IL5 IL4 IL13
5
Show member pathways
12.3 STAT6 IL5 IL4 IL13 CD4
6
Show member pathways
12.16 STAT6 IL5 IL4 IL13
7
Show member pathways
12.11 IL5 IL4 IL13
8
Show member pathways
11.86 IL5 IL4 IL13 CD4
9 11.8 IL5 IL4 CD4
10 11.77 STAT6 IL4 IL13
11
Show member pathways
11.75 STAT6 IL4 CD4
12 11.67 IL5 IL4 CD4
13 11.57 IL5 IL4 IL13
14 11.48 IL4 IL13 ARG1
15 11.46 IL5 IL4 IL13 CD4
16 11.41 IL5 IL4 IL13
17 11.26 STAT6 IL5 IL4 ARG1
18 11.11 IL5 IL4
19 11.09 IL5 IL4 IL13
20 11.02 IL13 CD4
21 10.99 IL5 IL4 IL13
22 10.91 IL5 IL4 IL13
23 10.72 IL5 IL4 IL13 CD4
24 10.68 STAT6 IL5 IL4 IL13 CD4

GO Terms for Intestinal Schistosomiasis

Biological processes related to Intestinal Schistosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.73 SNAI1 IL5 IL4 CD4
2 immune response GO:0006955 9.67 IL5 IL4 IL13 CD4
3 positive regulation of cold-induced thermogenesis GO:0120162 9.5 STAT6 IL4 IL13
4 negative regulation of endothelial cell apoptotic process GO:2000352 9.4 IL4 IL13
5 positive regulation of isotype switching to IgE isotypes GO:0048295 9.26 STAT6 IL4
6 negative regulation of complement-dependent cytotoxicity GO:1903660 9.16 IL4 IL13
7 positive regulation of B cell proliferation GO:0030890 9.13 IL5 IL4 IL13
8 cytokine-mediated signaling pathway GO:0019221 9.02 STAT6 IL5 IL4 IL13 CD4

Molecular functions related to Intestinal Schistosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.13 IL5 IL4 IL13
2 cytokine receptor binding GO:0005126 8.62 IL4 IL13

Sources for Intestinal Schistosomiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....